This is Evira
A medical technology company with roots in science and technology — founded at Karolinska Institutet and KTH Royal Institute of Technology. We believe every person with obesity has the right to effective, evidence-based care.
Our journey
2018 First clinical study results. Pilot at Martina Children's Hospital. CE marked Class I.
2019 Winner of Swedbank Rivstart and SEIF Award.
2020 Feasibility study published in BMC Pediatrics. Platform validated at three sites.
2022 One-year study in Int J Obesity. Expansion across Sweden.
2023 Won procurement from NHSE. Entered UK market.
2025 Three-year follow-up published — no weight regain. RCT for GLP-1 in adolescents initiated at 5 Swedish university clinics.
2026 7,000+ paediatric patients, 3,000+ adult users.
Evira is used here
The map shows UK locations that use Evira. Contact the Evira clinic in your vicinity if you would like to learn more about using Evira as a tool in your child's or young person's obesity treatment.